The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M. Ryckman; Bradley N. Reames; Kelsey Klute; William A. Hall; Michael J. Baine; May Abdel-Wahab; Chi Lin

doi:https://doi.org/10.1016/j.ctro.2021.04.002

doi.org/10.1016/j.ctro.2021.04.002

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

,

,

..., Chi Lin

70

Clinical and Translational Radiation Oncology3.10

Volume: 28, Pages: 124 - 128

Published: May 1, 2021

Abstract

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional...